UK personalised healthcare company, Concepta (CPT) is bringing their lead technology myLotus to Boots UK.
Launched in 2018, myLotus is a self-test women’s fertility and hormone tester, detecting the actual concentration of hormones-- an analysis which is not available with other traditional ovulation tests on the market.
The Boots supply agreement is Concepta’s first commercial partnership and aligns with the company’s larger EU roll-out plan.
myLotus recently received the CE-Mark certification, indicating it meets health, safety, and environmental protection standards for products sold within the European Economic Area. This new status allows for the technology to be sold online on Boots website, as well as to other partners across EU markets.
The market for such technologies is growing. Today, more than a quarter of women have used pregnancy apps and other technology aids to help them conceive, and 10% of women have spent more than £200 to increase their chances of getting pregnant.
The burgeoning fertility industry is worth more than £320 million in the UK alone.
And it seems the Boots partnership is only the beginning in Concepta’s roll-out. The company has also eyed distribution where market demands have already been determined.
For more news and updates on Concepta: